Home LiteratureArticle Details
PMID: 17016559 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells.

The Journal of clinical investigation ·Vol. 116 ·No. 10 ·2006-10-00 ·Pages 2777-90

Gallina G, Dolcetti L, Serafini P, De Santo C, Marigo I, Colombo MP, Basso G, Brombacher F, Borrello I, Zanovello P, Bicciato S, Bronte V

Abstract

Active suppression of tumor-specific T lymphocytes can limit the efficacy of immune surveillance and immunotherapy. While tumor-recruited CD11b+ myeloid cells are known mediators of tumor-associated immune dysfunction, the true nature of these suppressive cells and the fine biochemical pathways governing their immunosuppressive activity remain elusive. Here we describe a population of circulating CD11b+IL-4 receptor alpha+ (CD11b+IL-4Ralpha+), inflammatory-type monocytes that is elicited by growing tumors and activated by IFN-gamma released from T lymphocytes. CD11b+IL-4Ralpha+ cells produced IL-13 and IFN-gamma and integrated the downstream signals of these cytokines to trigger the molecular pathways suppressing antigen-activated CD8+ T lymphocytes. Analogous immunosuppressive circuits were active in CD11b+ cells present within the tumor microenvironment. These suppressor cells challenge the current idea that tumor-conditioned immunosuppressive monocytes/macrophages are alternatively activated. Moreover, our data show how the inflammatory response elicited by tumors had detrimental effects on the adaptive immune system and suggest novel approaches for the treatment of tumor-induced immune dysfunctions.

MeSH Terms
Animals Arginase/genetics,metabolism CD11b Antigen/analysis CD8-Positive T-Lymphocytes/immunology,metabolism Cell Line, Tumor Gene Expression/genetics Granulocyte-Macrophage Colony-Stimulating Factor/genetics,metabolism Immunity, Cellular/immunology Interferon-gamma/genetics,metabolism,pharmacology Interleukin-13/metabolism,pharmacology Interleukin-4/genetics,metabolism Lymphocyte Activation/immunology Mice Mice, Inbred BALB C Mice, Inbred C57BL Mice, Knockout Mice, Transgenic Models, Immunological Monocytes/drug effects,immunology,metabolism Myeloid Cells/drug effects,immunology,metabolism Neoplasms/immunology,metabolism,pathology Nitric Oxide Synthase Type II/genetics,metabolism Receptors, Cell Surface/analysis,genetics,metabolism Spleen/cytology,immunology T-Lymphocytes, Cytotoxic/immunology,metabolism
Chemicals
CD11b Antigen Il4ra protein, mouse Interleukin-13 Receptors, Cell Surface Interleukin-4 Interferon-gamma Granulocyte-Macrophage Colony-Stimulating Factor Nitric Oxide Synthase Type II Nos2 protein, mouse Arginase
Authors & Affiliations
12 authors, click to expand affiliations / ORCID
Gallina Giovanna
Istituto Oncologico Veneto, Padua, Italy.
Dolcetti Luigi
Serafini Paolo
De Santo Carmela
Marigo Ilaria
Colombo Mario P
Basso Giuseppe
Brombacher Frank
Borrello Ivan
Zanovello Paola
Bicciato Silvio
Bronte Vincenzo
References (47)
47 references, click to expand
  1. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis.
    Cancer Cell. 2004 Oct;6(4):409-21 PMID: 15488763
  2. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells.
    Cancer Res. 2004 Sep 1;64(17):6337-43 PMID: 15342423
  3. Inhibition of tumor growth by elimination of granulocytes.
    J Exp Med. 1995 Jan 1;181(1):435-40 PMID: 7807024
  4. Suppression of T cell proliferation by tumor-induced granulocyte-macrophage progenitor cells producing transforming growth factor-beta and nitric oxide.
    J Immunol. 1996 Mar 1;156(5):1916-22 PMID: 8596044
  5. Increased recurrence and metastasis in patients whose primary head and neck squamous cell carcinomas secreted granulocyte-macrophage colony-stimulating factor and contained CD34+ natural suppressor cells.
    Int J Cancer. 1997 Feb 20;74(1):69-74 PMID: 9036872
  6. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression.
    Proc Natl Acad Sci U S A. 1998 Feb 3;95(3):1178-83 PMID: 9448305
  7. Mechanisms of immune suppression in patients with head and neck cancer: presence of CD34(+) cells which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor.
    Clin Cancer Res. 1995 Jan;1(1):95-103 PMID: 9815891
  8. Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells.
    J Immunol. 1998 Nov 15;161(10):5313-20 PMID: 9820504
  9. Enhanced human cell engraftment in mice deficient in RAG2 and the common cytokine receptor gamma chain.
    Br J Haematol. 1998 Nov;103(2):335-42 PMID: 9827902
  10. Peroxynitrite inhibits T lymphocyte activation and proliferation by promoting impairment of tyrosine phosphorylation and peroxynitrite-driven apoptotic death.
    J Immunol. 1999 Mar 15;162(6):3356-66 PMID: 10092790
  11. IFN-gamma up-regulates the A2B adenosine receptor expression in macrophages: a mechanism of macrophage deactivation.
    J Immunol. 1999 Mar 15;162(6):3607-14 PMID: 10092821
  12. Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation.
    J Immunol. 1999 May 15;162(10):5728-37 PMID: 10229805
  13. Mechanisms and functional significance of tumour-induced dendritic-cell defects.
    Nat Rev Immunol. 2004 Dec;4(12):941-52 PMID: 15573129
  14. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease.
    J Immunol. 2005 Jan 15;174(2):636-45 PMID: 15634881
  15. Smoldering and polarized inflammation in the initiation and promotion of malignant disease.
    Cancer Cell. 2005 Mar;7(3):211-7 PMID: 15766659
  16. Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination.
    Proc Natl Acad Sci U S A. 2005 Mar 15;102(11):4185-90 PMID: 15753302
  17. STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion.
    J Immunol. 2005 Apr 15;174(8):4880-91 PMID: 15814715
  18. Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers.
    J Exp Med. 2005 Apr 18;201(8):1257-68 PMID: 15824085
  19. Reactive oxygen species and 12/15-lipoxygenase contribute to the antiproliferative capacity of alternatively activated myeloid cells elicited during helminth infection.
    J Immunol. 2005 May 15;174(10):6095-104 PMID: 15879104
  20. Regulation of immune responses by L-arginine metabolism.
    Nat Rev Immunol. 2005 Aug;5(8):641-54 PMID: 16056256
  21. Monocyte and macrophage heterogeneity.
    Nat Rev Immunol. 2005 Dec;5(12):953-64 PMID: 16322748
  22. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression.
    Semin Cancer Biol. 2006 Feb;16(1):53-65 PMID: 16168663
  23. A correlation between GM-CSF gene expression and metastases in murine tumors.
    Int J Cancer. 1991 Feb 1;47(3):413-20 PMID: 1993549
  24. IL-4 dependent alternatively-activated macrophages have a distinctive in vivo gene expression phenotype.
    BMC Immunol. 2002 Jul 4;3:7 PMID: 12098359
  25. Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence.
    J Exp Med. 2003 Dec 1;198(11):1741-52 PMID: 14657224
  26. Resection of solid tumors reverses T cell defects and restores protective immunity.
    J Immunol. 2000 Feb 15;164(4):2214-20 PMID: 10657677
  27. Cytokine-secreting tumor cell vaccines.
    Curr Opin Immunol. 2000 Oct;12(5):571-5 PMID: 11007361
  28. Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells.
    Blood. 2000 Dec 1;96(12):3838-46 PMID: 11090068
  29. Immortalized myeloid suppressor cells trigger apoptosis in antigen-activated T lymphocytes.
    J Immunol. 2000 Dec 15;165(12):6723-30 PMID: 11120790
  30. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer.
    J Immunol. 2001 Jan 1;166(1):678-89 PMID: 11123353
  31. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway.
    Nat Immunol. 2000 Dec;1(6):515-20 PMID: 11101874
  32. Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells.
    J Immunol. 2001 May 1;166(9):5398-406 PMID: 11313376
  33. Differences in normal values for murine white blood cell counts and other hematological parameters based on sampling site.
    Inflamm Res. 2001 Oct;50(10):523-7 PMID: 11713907
  34. Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism.
    J Immunol. 2002 Jan 15;168(2):689-95 PMID: 11777962
  35. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes.
    Trends Immunol. 2002 Nov;23(11):549-55 PMID: 12401408
  36. IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice.
    J Immunol. 2003 Jan 1;170(1):270-8 PMID: 12496409
  37. Alternative activation of macrophages.
    Nat Rev Immunol. 2003 Jan;3(1):23-35 PMID: 12511873
  38. Interleukin-4 and interleukin-13 signaling connections maps.
    Science. 2003 Jun 6;300(5625):1527-8 PMID: 12791978
  39. Blood monocytes consist of two principal subsets with distinct migratory properties.
    Immunity. 2003 Jul;19(1):71-82 PMID: 12871640
  40. Translational control of inducible nitric oxide synthase by IL-13 and arginine availability in inflammatory macrophages.
    J Immunol. 2003 Nov 1;171(9):4561-8 PMID: 14568929
  41. Effective genetic vaccination with a widely shared endogenous retroviral tumor antigen requires CD40 stimulation during tumor rejection phase.
    J Immunol. 2003 Dec 15;171(12):6396-405 PMID: 14662838
  42. Derangement of immune responses by myeloid suppressor cells.
    Cancer Immunol Immunother. 2004 Feb;53(2):64-72 PMID: 14593498
  43. Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer.
    J Immunol. 2004 Jan 1;172(1):464-74 PMID: 14688356
  44. Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species.
    J Immunol. 2004 Jan 15;172(2):989-99 PMID: 14707072
  45. Alternative macrophage activation is essential for survival during schistosomiasis and downmodulates T helper 1 responses and immunopathology.
    Immunity. 2004 May;20(5):623-35 PMID: 15142530
  46. The immunobiology of cancer immunosurveillance and immunoediting.
    Immunity. 2004 Aug;21(2):137-48 PMID: 15308095
  47. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses.
    Cancer Res. 2004 Aug 15;64(16):5839-49 PMID: 15313928
Article Info
Journal
The Journal of clinical investigation
Abbr.
J Clin Invest
ISSN
0021-9738
Published
2006-10-00
Pages
2777-90
Language
English
Region
United States
NLM ID
7802877
PMCID
PMC1578632
Subset
IM
Grants
NCI NIH HHS · P30 CA016672 · United States
Corrections
CommentIn
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com